Hepatitis B

HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs

Retrieved on: 
Montag, Januar 29, 2024
Patient, Neck, HNSCC, Arenavirus, Head, IND, HIV, Investigational New Drug, Workforce, Hepatitis B, Pembrolizumab, Pharmaceutical industry

The totality of the HB-200 data presents a clear opportunity for HOOKIPA to advance this program in a randomized trial starting in mid-2024.

Key Points: 
  • The totality of the HB-200 data presents a clear opportunity for HOOKIPA to advance this program in a randomized trial starting in mid-2024.
  • “HOOKIPA has a tremendous opportunity to transform treatment of multiple disease areas using an entirely new class of medicines,” said Joern Aldag, Chief Executive Officer at HOOKIPA.
  • HOOKIPA will reduce its workforce by approximately 30 percent and rebalance its cost structure in alignment with the new prioritization of the Company’s programs.
  • The strategic priorities for HOOKIPA are to advance its clinical programs including HB-200 and its two Gilead-partnered infectious disease programs.

Assembly Biosciences Provides Anticipated Development Milestones for 2024

Retrieved on: 
Donnerstag, Januar 4, 2024
Assembly, Partnership, Outline, Biotechnology, HDV, HBV, Trial of the century, Hepatitis B, Viral, HSV, Patient, Gilead Sciences, Vaccine

Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses

Key Points: 
  • Four development candidates anticipated to be in the clinic by the end of 2024, reflecting expansion of R&D portfolio across herpesviruses and hepatitis B and D viruses
    Recently announced long-term partnership with Gilead Sciences, Inc. (Gilead) to address serious viral diseases expands and builds on the progress of Assembly Bio’s antiviral portfolio
    SOUTH SAN FRANCISCO, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today provided an outline of the anticipated milestones and progress for its clinical pipeline during 2024.
  • “We are thrilled with the rapid progress of multiple programs from our expanded antiviral pipeline, and plan to initiate clinical studies for four development candidates in 2024,” said Jason Okazaki, chief executive officer and president of Assembly Bio.
  • By the end of 2024:
    Two additional candidates are anticipated to enter the clinic:
    ABI-1179, the long-acting HSV helicase-primase inhibitor contributed by Gilead under the collaboration between Assembly Bio and Gilead; and
    ABI-6250, a small molecule orally-bioavailable hepatitis delta virus entry inhibitor.
  • Initial clinical data are expected to be available from both the ABI-5366 first-in-human clinical study and the ABI-4334 Phase 1b study.

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Retrieved on: 
Dienstag, Januar 2, 2024
Liver, Marketing, MP, Heart, MRI, INN, Risk, MTX, Pneumonia, Fungus, AZA, UC, Eating, Inflammation, Ankylosing spondylitis, Infection, Fungal infection, Diagnosis, Anatomy, Ulcer, Lymphoma, IIA, Skin, Vasculitis, Yeast, Psoriasis, ATC, Joint, Pain, Psoriatic arthritis, Syringe, Disease, Nose, Allergy, Lower respiratory tract infection, Nonsteroidal anti-inflammatory drug, Hepatitis B virus, Safety, Heart failure, CRP, Disorder, Rheumatoid arthritis, Sepsis, Magnetic resonance imaging, Leukemia, Patient, Medical Subject Headings, Walking, Immune system, Ulcerative colitis, International, Arthritis, Language, Blood, Hepatitis B, Medication package insert, Tuberculosis, Select, Medicine, Methotrexate, Azathioprine, TNF, X-ray, Mercaptopurine, European Medicines Agency, Spine, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Simponi, golimumab, Date of authorisation: 01/10/2009, Revision: 49, Status: Authorised

AstriVax Awarded €3 Million Grant to Advance therapeutic Hepatitis B Vaccine

Retrieved on: 
Dienstag, Dezember 12, 2023
Research, Hepatitis B, Patient, Ecosystem, Hepatitis, Vaccination, Pharmaceutical industry

The grant will be used to accelerate the development of the company’s therapeutic vaccine targeting chronic Hepatitis B.

Key Points: 
  • The grant will be used to accelerate the development of the company’s therapeutic vaccine targeting chronic Hepatitis B.
  • The non-dilutive financing builds upon the award-winning €30 million seed financing raised in 2022 and the first VLAIO grant of €2.5 million to advance the innovative vaccine platform.
  • The company has received a grant of €3 million to advance its innovative technology in clinical development for one of the lead indications, chronic Hepatitis B.
    Hanne Callewaert, Ph.D., CEO of AstriVax, said: “I am honored that VLAIO recognizes the potential of our candidate vaccine targeting chronic Hepatitis B.
  • Combined with the award-winning €30 million in seed capital AstriVax raised in 2022 and the first VLAIO grant awarded on the vaccine platform itself, this VLAIO grant brings the company significantly closer to making a lasting impact in the Hepatitis B field.

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

Retrieved on: 
Dienstag, November 21, 2023
Partnership, HIV/AIDS, RSV, University, Biotechnology, CFO, Principal, Medical director, Hepatitis B, CMV, HPV, Therapy, Virus, Viral, Knowledge, Chairperson, COVID-19, OTCQB, HSV, CCR5, Internal medicine, Patient, Pharmaceutical industry

VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as interim CEO, effective November 17, 2023.

Key Points: 
  • VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, today announced the appointment of Dr. Jacob Lalezari as interim CEO, effective November 17, 2023.
  • Dr. Lalezari brings over 34 years of industry experience and has been a longtime adviser to the Company.
  • He previously served as interim Chief Medical Officer of CytoDyn during 2020, and has been a member of the Company’s scientific advisory board for the past several years.
  • Dr. Lalezari has been the CEO and Medical Director of Quest Clinical Research since 1996, and also served as the Chief Medical Officer of Virion Therapeutics in 2018.

Hatch BioFund Announces New Partnership with Brandywine Realty Trust

Retrieved on: 
Mittwoch, Dezember 20, 2023
Biotechnology, Technology, Professional Services, Health, General Health, Pharmaceutical, Other Science, Other Technology, Research, Science, Finance, Partnership, COVID-19, ARD International Music Competition, Nobel, Daiichi Sankyo, FDA, COVID-19 vaccine, Hepatitis, PABC, Hepatitis B, Brandywine Realty Trust, Business development, Hepatitis B Foundation, Growth, Pharmaceutical industry

Hatch BioFund Management LLC (“Hatch BioFund”), an early- stage life sciences venture capital firm headquartered in the Philadelphia region, and Brandywine Realty Trust (“Brandywine”), one of the largest, publicly traded, full-service, integrated real estate companies in the United States, announced today a new partnership to support the advancement of life sciences companies in Greater Philadelphia.

Key Points: 
  • Hatch BioFund Management LLC (“Hatch BioFund”), an early- stage life sciences venture capital firm headquartered in the Philadelphia region, and Brandywine Realty Trust (“Brandywine”), one of the largest, publicly traded, full-service, integrated real estate companies in the United States, announced today a new partnership to support the advancement of life sciences companies in Greater Philadelphia.
  • “We are proud that Brandywine selected Hatch BioFund as its investment partner,” said Lorenzo Pellegrini, Ph.D., managing partner of Hatch BioFund.
  • “Brandywine’s platform will be invaluable in our team’s effort to support the growth of exceptional life science entrepreneurs in the Greater Philadelphia region.
  • Additionally, Philadelphia was recently named one of five regions in the country to receive a biotechnology hub designation from the Biden administration.

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Retrieved on: 
Donnerstag, November 9, 2023
Hepatology, Research, Immune system, Depreciation, HBV, Hepatitis B, Arbutus, Vaccine, Liver, Infection, Healing, Cancer, Autoimmunity, Pharmaceutical industry, Vaccitech

OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress.

Key Points: 
  • OXFORD, United Kingdom, Nov. 09, 2023 (GLOBE NEWSWIRE) --  Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc, today announced its financial results for the third quarter of 2023 and provided an overview of its progress.
  • “The third quarter of 2023 was a period of solid progress for the Company.
  • We have since revealed the evolution of the company identity from Vaccitech to Barinthus Bio.
  • Cash position: As of September 30, 2023, the Company had cash and cash equivalents of $160.3 million, compared to $173.0 million as of June 30, 2023.

Electra Therapeutics Appoints Kathy Dong, PharmD, MBA, as President and Chief Executive Officer

Retrieved on: 
Montag, Dezember 11, 2023
Biotechnology, Pharmaceutical, Health, Star, Acquisition, University, Audit committee, Inflammation, Therapy, Commercial, Gilead Sciences, Doctor of Pharmacy, Hepatitis B, Patient, Multimedia, Hepatitis C, Hematology, MBA, Cancer, Antibody, True north, Growth, Doctor of Philosophy, American Society of Hematology, Cold agglutinin disease, Society, Rutgers University, Biology, Pharmaceutical industry, Management, Sanofi

Electra Therapeutics, Inc. , a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.

Key Points: 
  • Electra Therapeutics, Inc. , a clinical stage biotechnology company developing antibody therapies against novel targets for immunological diseases and cancer, today announced the appointment of Kathy Dong, PharmD, MBA, as President and Chief Executive Officer.
  • View the full release here: https://www.businesswire.com/news/home/20231211224486/en/
    Electra President and CEO Kathy Dong PharmD, MBA (Photo: Business Wire)
    “We are excited to have Kathy take on the role of CEO of Electra.
  • Dr. Rosenthal will continue to serve as a member of Electra’s board of directors and as Chief Executive Officer of Star Therapeutics, the company that spun out Electra.
  • Previously, she was Chief Operating Officer of Star Therapeutics since 2019, where she held strategic and operational responsibilities across the Star portfolio, including building Electra Therapeutics and Vega Therapeutics from discovery stage into the clinic.

AI Revolutionizes HBV Vaccine Development as Global Market Grows at a CAGR of 5.33% - ResearchAndMarkets.com

Retrieved on: 
Donnerstag, November 9, 2023
Technology, Infectious Diseases, Health, Artificial Intelligence, WHO, Bioinformatics, LG Chem, Drug design, Intelligence, Composition, Incidence, Pregnancy, Vaccine, Government, ROW, Prevalence, Indian Immunologicals Limited, GSK plc, Merck, Data science, Mother, Vaccination, Liver cancer, Genomics, Transport, COVAX, COVID-19, Antibody, KM, Microbiology, Machine learning, Biochemistry, Blood, Hepatitis A and B vaccine, Serum, Hepatitis B virus, Public, Sanofi, Hepatitis, Hepatitis B, Immunization, Pediatrics, World Health Organization's response to the COVID-19 pandemic, Compound annual growth rate, HBV, Parent, Cirrhosis, Merck & Co.

The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.

Key Points: 
  • The HBV vaccine stands as a crucial tool in the World Health Organization's (WHO) mission to eliminate HBV by 2030.
  • Since the approval of the first HBV vaccine in 1981, significant advancements have occurred in the development of HBV vaccines.
  • The United States leads the global market due to a high demand for the HBV vaccine, driven by ongoing HBV infection threats.
  • The integration of AI in vaccine and drug design is poised to accelerate vaccine development, enhance efficacy, and drive the HBV vaccine market's growth.

Assembly Biosciences Reports Third Quarter 2023 Financial Results and Recent Updates

Retrieved on: 
Mittwoch, November 8, 2023
Research, IND, American Association for the Study of Liver Diseases, International, Infection, HSV, Therapy, Hepatology, Viral, Biotechnology, Liver, Viral hepatitis, Hepatitis D, Doctor of Philosophy, Gilead Sciences, Assembly, Partnership, Virology, Hepatitis B, Patient, HDV, HBV, AASLD, Pharmaceutical industry, Vaccine, Birth control, MD

Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond

Key Points: 
  • Established partnership with Gilead Sciences to advance differentiated treatments for herpesviruses, HBV, HDV and beyond
    SOUTH SAN FRANCISCO, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative antiviral therapeutics targeting serious viral diseases, today reported financial results for the third quarter ended September 30, 2023, and recent corporate updates.
  • We believe that the financial and scientific resources provided by the collaboration position us well to reach critical short- and long-term milestones and deliver value for patients and our shareholders.
  • Partnership includes Gilead opt-in rights on Assembly Bio’s current and future pipeline candidates, including two contributed Gilead herpesvirus programs.
  • Cash, cash equivalents and marketable securities were $46.2 million as of September 30, 2023, compared to $59.8 million as of June 30, 2023.